RE:RE:U.S. On the regulatory front, the US has been kinder to TH than Europe. TH has always been able to get things through the FDA, if only narrowly. But the EMA shot down Egrifta for lipo even after the FDA had approved it and now they are apparently not willing to go along with the NASH phase III. I suspect having Dr. Loomba on our team really helped get the pahse III across the finish line with the FDA but that no comparable consultant was in place at the EMA.
On the issue of Paul and Leah, it is very surprising that we have not seen more benefit in the stock price since their arrival. It is hard to explain that.
qwerty22 wrote: Seems true of the majority of Canadian biotechs, there are exceptions though. I was hoping Paul came with a US network of contacts, maybe even Leah had built something to tap into. Doesn't seem much evidence of that though.
Bucknelly21 wrote: Maybe the u.s. just doesn't like Thtx. This is pathetic